Phase IB Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant in Patients With Metastatic Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 05 Aug 2013 Biomarkers information updated
- 09 Jun 2009 Planned number of patients changed from 5 to 25 as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.